News Sentiment

BMRA sentiment intelligence

Biomerica Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 52 Balanced news tone 51 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Medical Devices Read-through group
Latest close 1.69 Week of 10 Jul 2026
Weighted tone 52/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Earnings

74/100 classification confidence.

Company focus 40

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

-3.4% over one week, -17.6% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

BMRA - Biomerica Inc Short Interest

Market Reaction

Balanced read

58/100 confidence

News tone and price action are not far from neutral.

Primary event Earnings 74/100 classification
One-week reaction -3.4% Price reacting lower
Trend fit Trend inactive -17.6% over four weeks
Fair value -61.8% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 11
Neutral 32
Negative 8

Relevance

Why the article matched

Direct first
Direct company coverage 40
Industry context 11
Sector context 0

Sources

Coverage mix

Publishers
Market source 9
TradingKey 8
TradingView 4
Finviz 3
DonanımHaber 3
Stock Titan 3
GuruFocus 3
StockStory 2

Event Lens

What the news is about

Classified themes
Earnings 22
Market update 16
Deals and strategy 10
Guidance 2
Regulatory and legal 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 51
Finviz Direct company coverage

BMRA - Biomerica Inc Short Interest

This article provides a detailed financial overview and short interest data for Biomerica Inc. (BMRA). It includes key metrics such as market capitalization, sales, earnings per share, profit margins, and various performance indicators. The data also highlights the short interest

Tone
Neutral 50/100
Event
Earnings
Published
06 Jul 2026 00:10
Source
Finviz
Finviz Direct company coverage

BMRA - Biomerica Inc Earnings

This page provides an overview of Biomerica Inc.'s (BMRA) financial performance and key metrics. It includes details such as market capitalization, sales, income, EPS, insider ownership, institutional ownership, profitability ratios, and stock performance data. The company's stoc

Tone
Negative 34/100
Event
Earnings
Published
04 Jul 2026 23:39
Source
Finviz
TradingView Direct company coverage

Enterprise value to EBITDA forward of Biomerica, Inc. – NASDAQ:BMRA

The article focuses on the enterprise value to EBITDA forward for Biomerica, Inc. (NASDAQ: BMRA). It appears to be a financial data page from TradingView, displaying stock information and financial metrics for the company. The content also mentions the data sources and copyright

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 13:40
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Biomerica, Inc. – NASDAQ:BMRA

This article provides financial data for Biomerica, Inc. (NASDAQ: BMRA), focusing on its forward price-to-sales ratio. It indicates that the market was closed with no trades at the time of reporting. The content is primarily a data page from TradingView, offering financial and ma

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 09:11
Source
TradingView
TradingKey Direct company coverage

Biomerica Inc (BMRA) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Biomerica Inc (BMRA), stating its current valuation score is 7.63, ranking 142 out of 203 in its industry. It highlights the company's current P/E ratio at -1.08, noting it is significantly below its recent high and above its recent l

Tone
Neutral 50/100
Event
Market update
Published
24 Jun 2026 19:11
Source
TradingKey
TradingKey Direct company coverage

Biomerica Inc (BMRA) Financial Health: Profitability & Balance Sheet Analysis

Biomerica Inc (BMRA) currently has a financial score of 6.12, ranking 174 out of 204 in the Healthcare Equipment & Supplies industry, indicating robust financial status but low operating efficiency. Its latest quarterly revenue saw an 11.80% year-over-year decrease to $987.00K, a

Tone
Negative 35/100
Event
Earnings
Published
23 Jun 2026 07:11
Source
TradingKey
TradingKey Direct company coverage

Biomerica Inc (BMRA) Earnings Forecast: Future EPS & Revenue Growth Estimates

The article provides an earnings forecast for Biomerica Inc (BMRA), noting that no earnings forecast score is currently available for the company. It indicates that the Healthcare Equipment & Supplies industry average score is 7.78. The page also displays current stock informatio

Tone
Negative 38/100
Event
Earnings
Published
19 Jun 2026 07:38
Source
TradingKey
TradingKey Direct company coverage

Biomerica Inc (BMRA) Institutional Confidence

This article from TradingKey focuses on the institutional confidence score for Biomerica Inc (BMRA), which stands at 3.00, unchanged as of June 18, 2026. It details the shareholdings and activity of several key individual and institutional shareholders, highlighting changes in th

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 16:40
Source
TradingKey
TradingKey Direct company coverage

Biomerica Inc (BMRA) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Biomerica Inc.'s (BMRA) dividend history and stock split events. It indicates that the company has distributed no dividends in the past five years and notes a merger-type stock split event scheduled for April 16, 2025, with an 8-for-1 ratio. T

Tone
Neutral 50/100
Event
Deals and strategy
Published
17 Jun 2026 16:38
Source
TradingKey
TradingKey Direct company coverage

Biomerica Inc (BMRA) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Biomerica Inc (BMRA), detailing its current price momentum score as 4.88, trading between a resistance level of $2.34 and a support level of $1.75. The analysis includes various technical indicators like MACD, RSI, and moving averages

Tone
Negative 10/100
Event
Market update
Published
17 Jun 2026 16:11
Source
TradingKey
TradingKey Direct company coverage

Biomerica Inc (BMRA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a detailed revenue breakdown for Biomerica Inc (BMRA), categorizing its revenue by business segment and geographical region. As of FY2026Q2, Clinical Lab and OTC segments are the largest contributors, while the United States and Asia lead in regional revenue

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 15:40
Source
TradingKey
TradingKey Direct company coverage

Biomerica Inc (BMRA) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Biomerica Inc (BMRA), outlining both individual major shareholders and institutional holdings. It provides a breakdown of proportional ownership for key individuals like Zackary S. Irani, Allen Barbieri, and Gary Lu, as well as sh

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 15:40
Source
TradingKey
TradingView Direct company coverage

Biomerica to Sell 6% Diagnosis Stake for $500,000; Issues 8% Note Pending Transfer

Biomerica has agreed to sell a 6% stake in Diagnosis for $500,000 to affiliates of CEO Zackary Irani. Pending Polish approvals, Biomerica issued a secured 12-month note at 8% to hold the funds, which will be forgiven upon closing, except for 60 days of interest. The transaction i

Tone
Positive 64/100
Event
Deals and strategy
Published
04 Jun 2026 21:10
Source
TradingView
Stock Titan Direct company coverage

Biomerica (BMRA) sells 6% Diagnosis S.A. stake to CEO-affiliated buyers

Biomerica, Inc. has entered into an agreement to sell 78,750 shares of Diagnosis S.A., roughly 6% of its outstanding shares, to buyers affiliated with its CEO, Zackary Irani, for $500,000. The transaction involves a secured promissory term note bearing 8% annual interest, maturin

Tone
Neutral 50/100
Event
Deals and strategy
Published
04 Jun 2026 21:10
Source
Stock Titan
Finviz Direct company coverage

BMRA - Biomerica Inc Stock Price and Quote

This article provides a detailed financial overview and recent news for Biomerica Inc. (BMRA), including its stock price, market capitalization, key financial ratios, and performance metrics. It also lists recent company announcements, such as new product approvals, clinical stud

Tone
Positive 66/100
Event
Market update
Published
30 May 2026 21:40
Source
Finviz
Medical Buyer Direct company coverage

Biomerica secures USD 1.75M contract for IVD diagnostic development

Biomerica, Inc. has secured a Master Services Agreement with a confidential life sciences company for over $1.75 million to develop proprietary in vitro diagnostic (IVD) assays. This CDMO engagement leverages Biomerica's existing ELISA-based assay development expertise and infras

Tone
Positive 74/100
Event
Deals and strategy
Published
30 May 2026 05:39
Source
Medical Buyer
www.geneonline.com Direct company coverage

Biomerica Inc. Awarded $1.75 Million Contract for IVD Product Development

Biomerica Inc. has secured a $1.75 million contract under a Master Services Agreement for the development of in vitro diagnostic (IVD) products. Operating as a contract development and manufacturing organization (CDMO), Biomerica will provide comprehensive services including prod

Tone
Positive 81/100
Event
Deals and strategy
Published
29 May 2026 07:40
Source
www.geneonline.com
The Manila Times Direct company coverage

Biomerica Lands a $1.75 Million CDMO Master Services Agreement for IVD Diagnostic Development

Biomerica, Inc. announced it has secured a Master Services Agreement with a confidential life sciences company for over $1.75 million to develop proprietary in vitro diagnostic (IVD) assays. This agreement leverages Biomerica's existing ELISA-based assay development expertise and

Tone
Positive 74/100
Event
Market update
Published
29 May 2026 07:39
Source
The Manila Times
Investing.com Direct company coverage

Biomerica signs contract development deal worth over $1.75M

Biomerica, Inc. announced a Master Services Agreement with an undisclosed life sciences company, valued at over $1.75 million, to develop in vitro diagnostic assays. This deal provides significant near-term revenue visibility for Biomerica, which has recently faced a 23.8% revenu

Tone
Positive 67/100
Event
Deals and strategy
Published
28 May 2026 20:09
Source
Investing.com
Investing.com Nigeria Direct company coverage

Biomerica signs contract development deal worth over $1.75M By Investing.com

Biomerica, Inc. has secured a Master Services Agreement worth over $1.75 million with an undisclosed life sciences company to develop in vitro diagnostic assays. This deal provides near-term revenue visibility for Biomerica, which has been facing revenue challenges, but also come

Tone
Positive 70/100
Event
Deals and strategy
Published
28 May 2026 19:09
Source
Investing.com Nigeria
Orange County Business Journal Direct company coverage

Biomerica Wins $1.75M Contract to Develop Diagnostic Tests

Biomerica Inc. has secured a $1.75 million master services agreement with an undisclosed life sciences company to develop in vitro diagnostic assays. The three-year contract involves all development work being performed at Biomerica’s Irvine facility. This agreement provides near

Tone
Positive 67/100
Event
Deals and strategy
Published
28 May 2026 17:40
Source
Orange County Business Journal
GuruFocus Direct company coverage

Biomerica (BMRA) Secures Master Services Agreement for Diagnostic Development

Biomerica Inc. (BMRA) has announced a significant master services agreement with a private life sciences firm for the development of specialized in vitro diagnostic assays, including an initial contract target fee exceeding $1.75 million. Despite this new partnership, the company

Tone
Neutral 50/100
Event
Deals and strategy
Published
28 May 2026 16:40
Source
GuruFocus
Stock Titan Direct company coverage

Undisclosed $1.75M lab deal taps Biomerica’s diagnostic test expertise

Biomerica (Nasdaq: BMRA) has secured a three-year, auto-renewing CDMO Master Services Agreement with a confidential life sciences partner to develop proprietary IVD assays. This agreement targets over $1.75 million in initial development fees and will leverage Biomerica's existin

Tone
Positive 74/100
Event
Deals and strategy
Published
28 May 2026 12:40
Source
Stock Titan